Forecast: (BCRX) for 2023-2027
BioCryst Pharmaceuticals icon

Forecast: (BCRX) for 2023-2027

Updated: October 26, 2023

An Insight into BioCryst Pharmaceuticals, Inc.

Ticker: BCRX

Sector: Healthcare

Closing price of the last trading day: $

Last trading day: 01/01/1970

Analyst forecast price: $18.6

52-week high/low: $19.99 / $7.61

On the global stage, BioCryst Pharmaceuticals, Inc. commands attention, with its shares actively traded under the ticker BCRX. A notable entity in the "Healthcare" sector, it showcases a blend of innovation and market resilience. Nestled at 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US, the head office stands as a nexus where strategic decisions and innovations emanate. It boasts a market capitalization of $2 599 511 000, reflecting its substantial footprint in the industry. With 185 945 000 shares oscillating in the vibrant market, every transaction echoes the company’s undeterred progression. A glimpse into the last fiscal year reveals EBITDA standing at -180 388 000$. It indicates a phase of economic recalibration, a precursor to potential upswings.

Engaging in a deeper analytical discourse, investors and market watchers alike often turn to resources like Here, comprehensive insights, data analytics, and predictive metrics about companies like BioCryst Pharmaceuticals, Inc. are made available. This rich reservoir of information aids in informed decision-making, blending historical data with future predictions to paint a holistic picture of stock performance trajectories.

Unraveling BioCryst Pharmaceuticals (BCRX) Stock Predictions for 2023

In the dynamic world of stock trading, precise and comprehensive forecasts are crucial. For investors eyeing BioCryst Pharmaceuticals and its promising trajectory, we have meticulously collated insights from various analyst forecasts. Our consensus forecast for 2023 is a composite reflection of diverse expert analyses, ensuring a balanced and informed perspective for potential investors and market enthusiasts.

We encapsulate our insights visually, offering a detailed forecast chart for BioCryst Pharmaceuticals in 2023. This visual representation is a blend of historical and projected data, offering a comprehensive view of the stock’s performance. The grey trajectory delineates the historical performance of BCRX, while the turquoise trajectory illuminates the anticipated performance, encapsulating potential fluctuations and trends.

At, we go beyond conventional data presentation. Our analyses are ingrained with depth, offering not just numbers but insights that empower informed decision-making. For BioCryst Pharmaceuticals, each data point, each trend, and each projection is a story of potential opportunities, risks, and strategic decisions. Navigate through the intricate world of stocks with data that is as comprehensive as it is precise.

Analyzing the anticipated performance of BioCryst Pharmaceuticals, the ceiling value that the stock is expected to reach within the current year stands at a promising $6.88. Indicating a bullish trend, an upside potential of 15% signals profitable prospects, with an average monthly return of 7.5%, beckoning investors to consider amplifying their portfolios.

On the flip side, the floor value that BioCryst Pharmaceuticals stock may plummet to this year is $5.76. Highlighting a potential decline of 3.79%, cautious investment and vigilant monitoring become paramount.

In the grand scheme, a price oscillation channel for BioCryst Pharmaceuticals is foreseeable, bounded by a resistance level of $6.88 and a support frontier at $5.76. This fluctuation breadth of $1.12 presents nuanced investment gateways and exit junctures, pivotal for strategic stock trading.

The pendulum of market dynamics sways amidst myriad factors. The juxtaposition of historical trends, current market sentiments, and forward-looking analytics offers a comprehensive panorama. The breakout potential, trajectory sustenance, and market volatilities are intrinsically tied to economic indicators, policy shifts, and industry innovations. For BioCryst Pharmaceuticals, every forecast, every percentage point, and every market prediction is not just a statistical data point but a narrative woven into the fabric of its corporate journey. As investors and market watchers alike toggle between optimism and caution, each prediction, each high and low, charts the course of BioCryst Pharmaceuticals in the bustling marketplace.

Ascend or descend, each move of BioCryst Pharmaceuticals stock is a pulse in the financial markets, echoing the rhythms of economic cycles, investor sentiments, and market dynamics. With the dawn of each trading day, new opportunities and challenges emerge, painting a vibrant tapestry of BioCryst Pharmaceuticals's stock trajectory in the canvas of global finance.

Let’s delve into an analytical exploration of the support level's robustness for BioCryst Pharmaceuticals stocks. The stock is projected to hover around the support level for 1 month, reflecting the temporal dynamics of BioCryst Pharmaceuticals's stock price. The resilience of the existing support level underscores its reliability, minimizing the likelihood of a downtrend.

Furthermore, it's pivotal to consider that the actual future valuation of BioCryst Pharmaceuticals shares is susceptible to market volatilities and can oscillate both above and below the anticipated forecast price. Yet, it is generally anticipated to oscillate within the confines of the pessimistic and optimistic target price projections. This nuance is integral for investors aiming for balanced portfolio diversification and risk mitigation.

Each projection and statistical insight into BioCryst Pharmaceuticals's performance not only informs investment strategies but also adds a layer to the unfolding narrative of its market journey. As numbers dance and trends oscillate, every investor, analyst, and market enthusiast becomes a witness to the dynamic ballet of figures, forecasts, and financial crescendos that define the stock’s story.

With the interplay of data, predictions, and real-time performance, BioCryst Pharmaceuticals's stock emerges not just as an investment opportunity but as a narrative unfolding in the grand theatre of the financial markets. Each high, low, surge, and dip is a chapter, and every investor, a reader and co-author of this evolving tale.
Table of forecasts for 2023.
Month Mid Low High Range, %
November 2023 6.23 5.76 6.58 12.50 %
December 2023 6.56 6.11 6.88 11.22 %

Forecast for November 2023.

It is predicted that the price of one BioCryst Pharmaceuticals share in will be in the range of $5.76 to $6.58. The width of this range will be $0.82 (12.50%). The average price is $6.23, which is $6.23 higher than the average price of the previous month.

Forecast for December 2023.

It is predicted that the price of one BioCryst Pharmaceuticals share in will be in the range of $6.11 to $6.88. The width of this range will be $0.77 (11.22%). The average price is $6.56, which is $0.33 higher than the average price of the previous month.

Read more

Denial of responsibility:

All submitted consensus forecasts are exposed to get acquainted with the algorithm for collecting forecasts and bringing them to a single whole. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.